智通财经APP讯，三生制药(01530)发布公告，自2024年6月13日至2024年6月28日，根据2023年购回授权及2024年购回授权(视情况而定)，公司于香港联合交易所有限公司进行了一系列股份购回，作为库存股份而持有。截至本公告日期，公司已购回合共2122.7万股股份作为库存股份，占截至本公告日期已发行股份总数的约0.89%(不包括库存股份)。该等库存股份已于本公告日期注销。
于库存股份注销后，公司不再拥有任何库存股份，而已发行股份总数为23.96亿股股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.